CinCor Pharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 19

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.76B

  • Investors
  • 2

CinCor Pharma General Information

Description

Developer of cardiovascular, metabolic, and kidney disease drugs designed to advance promising clinical candidates toward marketing approval. The company is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.

Contact Information

Website
www.cincor.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 230 Third Avenue
  • 6th Floor
  • Waltham, MA 02451
  • United States
+1 (513)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 230 Third Avenue
  • 6th Floor
  • Waltham, MA 02451
  • United States
+1 (513)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CinCor Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Feb-2023 $1.76B Completed Generating Revenue
4. 2PO 12-Aug-2022 Completed Generating Revenue
3. IPO 07-Jan-2022 Completed Generating Revenue
2. Early Stage VC (Series B) 22-Sep-2021 $143M $193M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 14-May-2019 $50M $50M Completed Clinical Trials - Phase 2
To view CinCor Pharma’s complete valuation and funding history, request access »

CinCor Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view CinCor Pharma’s complete cap table history, request access »

CinCor Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cardiovascular, metabolic, and kidney disease drugs designed to advance promising clinical candidates towar
Drug Discovery
Waltham, MA
19 As of 2022

Wayne, PA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CinCor Pharma Competitors (67)

One of CinCor Pharma’s 67 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aclaris Therapeutics Formerly VC-backed Wayne, PA
Rein Therapeutics Formerly VC-backed Austin, TX
Zealand Pharma Formerly VC-backed Soborg, Denmark
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 67 competitors. Get the full list »

CinCor Pharma Patents

CinCor Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023320092-A1 Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat Pending 05-Aug-2022
EP-4565235-A1 Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat Active 05-Aug-2022
US-20260041679-A1 Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat Pending 05-Aug-2022
WO-2024030615-A1 Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat Inactive 05-Aug-2022
JP-2025525936-A Methods for treating hypertension with the aldosterone synthase inhibitor baxdrostat Pending 05-Aug-2022 A61K31/4725
To view CinCor Pharma’s complete patent history, request access »

CinCor Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CinCor Pharma Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
5AM Ventures Venture Capital Minority
Adage Capital Management Hedge Fund Minority
BVF Partners Hedge Fund Minority
General Atlantic Growth/Expansion Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

CinCor Pharma ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view CinCor Pharma’s complete esg history, request access »

CinCor Pharma FAQs

  • When was CinCor Pharma founded?

    CinCor Pharma was founded in 2018.

  • Where is CinCor Pharma headquartered?

    CinCor Pharma is headquartered in Waltham, MA.

  • What is the size of CinCor Pharma?

    CinCor Pharma has 19 total employees.

  • What industry is CinCor Pharma in?

    CinCor Pharma’s primary industry is Drug Discovery.

  • Is CinCor Pharma a private or public company?

    CinCor Pharma is a Private company.

  • What is the current valuation of CinCor Pharma?

    The current valuation of CinCor Pharma is .

  • What is CinCor Pharma’s current revenue?

    The current revenue for CinCor Pharma is .

  • How much funding has CinCor Pharma raised over time?

    CinCor Pharma has raised $533M.

  • Who are CinCor Pharma’s investors?

    5AM Ventures, Adage Capital Management, BVF Partners, General Atlantic, and LAV (Lilly Asia Fund) are 5 of 13 investors who have invested in CinCor Pharma.

  • Who are CinCor Pharma’s competitors?

    Aclaris Therapeutics, Rein Therapeutics, Zealand Pharma, Sarepta Therapeutics, and Sorrento Therapeutics are some of the 67 competitors of CinCor Pharma.

  • When was CinCor Pharma acquired?

    CinCor Pharma was acquired on 24-Feb-2023.

  • Who acquired CinCor Pharma?

    CinCor Pharma was acquired by AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process